American Vietnamese Biotech Incorporation (HNX:AMV)
Vietnam · Delayed Price · Currency is VND 1,300.00
0.00 (0.00%)
At close: Jul 20, 2026
HNX:AMV Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 97,745 | 154,067 | 310,355 | 196,570 | 281,818 | 223,843 | |
Revenue Growth (YoY) | -70.20% | -50.36% | 57.88% | -30.25% | 25.90% | 38.66% |
Cost of Revenue | 85,008 | 132,371 | 279,093 | 146,978 | 202,869 | 110,149 |
Gross Profit | 12,738 | 21,696 | 31,261 | 49,592 | 78,949 | 113,694 |
Selling, General & Admin | 49,582 | 49,279 | 35,574 | 17,122 | 15,478 | 14,028 |
Operating Expenses | 49,582 | 49,279 | 35,574 | 17,122 | 15,478 | 14,028 |
Operating Income | -36,845 | -27,583 | -4,313 | 32,471 | 63,472 | 99,666 |
Interest Expense | -14,997 | -18,539 | -19,650 | -23,353 | -20,309 | -18,124 |
Interest & Investment Income | 2,530 | 2,314 | 739.98 | 1,153 | 2,511 | 3,482 |
Earnings From Equity Investments | -6,073 | -6,073 | -1,886 | - | - | - |
Currency Exchange Gain (Loss) | - | - | 643.38 | 1,164 | - | - |
Other Non Operating Income (Expenses) | -4,484 | -4,343 | 1,767 | -1,625 | 10,812 | -3,417 |
EBT Excluding Unusual Items | -59,869 | -54,224 | -22,699 | 9,809 | 56,487 | 81,608 |
Gain (Loss) on Sale of Assets | - | - | 11,209 | 1,641 | - | - |
Pretax Income | -59,869 | -54,224 | -11,491 | 11,450 | 56,487 | 81,608 |
Income Tax Expense | -504.78 | 280.08 | 1,575 | 718.26 | 1,316 | - |
Earnings From Continuing Operations | -59,364 | -54,504 | -13,065 | 10,732 | 55,171 | 81,608 |
Minority Interest in Earnings | 1,435 | 1,454 | 1,874 | -47.13 | -1,239 | 631.67 |
Net Income | -57,929 | -53,049 | -11,191 | 10,685 | 53,931 | 82,240 |
Net Income to Common | -57,929 | -53,049 | -11,191 | 10,685 | 53,931 | 82,240 |
Net Income Growth | - | - | - | -80.19% | -34.42% | 5.36% |
Shares Outstanding (Basic) | 130 | 131 | 131 | 131 | 107 | 84 |
Shares Outstanding (Diluted) | 130 | 131 | 131 | 131 | 107 | 84 |
Shares Change (YoY) | -1.11% | -0.09% | - | 22.04% | 27.63% | 58.37% |
EPS (Basic) | -444.95 | -405.00 | -85.36 | 81.50 | 502.00 | 977.00 |
EPS (Diluted) | -444.95 | -405.00 | -85.36 | 81.00 | 502.00 | 977.00 |
EPS Growth | - | - | - | -83.86% | -48.62% | -33.47% |
Free Cash Flow | 117,657 | 246,626 | 628,530 | -144,792 | -347,688 | -510,894 |
Free Cash Flow Per Share | 903.73 | 1882.84 | 4794.07 | -1104.39 | -3236.32 | -6069.36 |
Gross Margin | 13.03% | 14.08% | 10.07% | 25.23% | 28.01% | 50.79% |
Operating Margin | -37.70% | -17.90% | -1.39% | 16.52% | 22.52% | 44.52% |
Profit Margin | -59.27% | -34.43% | -3.61% | 5.44% | 19.14% | 36.74% |
Free Cash Flow Margin | 120.37% | 160.08% | 202.52% | -73.66% | -123.37% | -228.24% |
EBITDA | -5,774 | 5,327 | 12,012 | 54,302 | 83,871 | 115,543 |
EBITDA Margin | -5.91% | 3.46% | 3.87% | 27.63% | 29.76% | 51.62% |
D&A For EBITDA | 31,071 | 32,910 | 16,325 | 21,832 | 20,399 | 15,877 |
EBIT | -36,845 | -27,583 | -4,313 | 32,471 | 63,472 | 99,666 |
EBIT Margin | -37.69% | -17.90% | -1.39% | 16.52% | 22.52% | 44.52% |
Effective Tax Rate | - | - | - | 6.27% | 2.33% | - |
Revenue as Reported | 97,745 | 154,067 | 310,355 | 196,570 | 281,818 | 223,843 |